Drug Search Results
More Filters [+]

Linezolid

Alternative Names: linezolid, zyvox, linox, linezolid in sodium chloride 0.9% in plastic container
Latest Update: 2024-07-04
Latest Update Note: Clinical Trial Update

Product Description

Linezolid is used to treat infections, including pneumonia, and infections of the skin . Linezolid is in a class of antibacterials called oxazolidinones. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a602004.html)

Mechanisms of Action: Protein Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Linezolid

Countries in Clinic: Belarus, Brazil, China, France, Georgia, India, Kazakhstan, Mexico, Pakistan, Peru, Philippines, Romania, Russia, South Africa, Spain, Ukraine, United States, Unknown Location, Uzbekistan, Vietnam

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: Bronchitis|Communicable Diseases|Diabetic Foot|Extensively Drug-Resistant Tuberculosis|Fractures, Open|Gram-Positive Bacterial Infections|Mycobacterium Infections|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Skin Ulcer|Soft Tissue Infections|Tuberculosis, Multidrug-Resistant|Tuberculosis, Pulmonary|Yaws

Phase 2: Acute Respiratory Distress Syndrome|Febrile Neutropenia

Phase 1: Bacteremia|Community-Acquired Infections|Osteomyelitis|Pneumonia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DRAMATIC

P2

Recruiting

Tuberculosis, Multidrug-Resistant

2027-05-01

DURATIOM

P3

Not yet recruiting

Fractures, Open

2026-01-31

endTB-Q

P3

Active, not recruiting

Tuberculosis, Multidrug-Resistant|Tuberculosis, Pulmonary|Mycobacterium Infections|Communicable Diseases|Gram-Positive Bacterial Infections

2024-09-01

Trep-AByaws

P3

Active, not recruiting

Yaws|Skin Ulcer

2024-06-20

Recent News Events